The global Substance Abuse Treatment Market is experiencing a surge, with its value projected to skyrocket from $11.8 billion in 2023 to an estimated $22.8 billion by 2031. This remarkable growth, anticipated to maintain a compound annual growth rate (CAGR) of 5.4% from 2023 to 2031, is a direct result of the escalating rates of addiction across the globe.
Several factors contribute to this trend, including increased social acceptance of substance use, the readily available supply of illegal drugs, and the ever-present challenges of stress and mental health issues. As more individuals develop dependencies, the demand for effective treatment options rises. This expanding patient pool diagnosed with substance abuse serves as a primary driver propelling the substance abuse treatment market forward.
Various treatment modalities are available, catering to diverse needs. These include inpatient programs, outpatient services, and medication therapies. The market is also witnessing the emergence of innovative treatment approaches, such as digital therapeutics, which leverage technology to provide remote treatment and monitoring. The growing acceptance and funding of these innovative options further fuel the market’s growth.
The global substance abuse treatment market is experiencing significant growth due to the rising prevalence of drug and substance abuse worldwide. According to the World Drug Report 2022 by the United Nations Office on Drugs and Crime, approximately 36.3 million people globally suffer from drug use disorders, and around 686,000 individuals lost their lives due to drug use in 2020. Alcohol, unfortunately, ranks as the world’s third leading cause of ill health and premature death. Easy access to drugs and peer pressure are key contributors to the global surge in substance abuse.
The market is witnessing a shift towards digital therapeutic solutions. Drug and alcohol de-addiction centers are increasingly adopting these technologies to offer remote treatment and monitoring for patients. Wearable biosensing devices and mobile applications that assist in tracking drug and alcohol intake in patients are gaining popularity in substance abuse treatment. For instance, Dance Biopharm has introduced a Saliva Test Strip, providing instant color-coded results to indicate the presence of drugs in saliva. Additionally, Orexo’s vorvida digital therapeutic platform provides at-home substance use disorder treatment plans through mobile tools. This widespread adoption of digital innovations is expected to play a pivotal role in shaping the future growth trajectory of the global substance abuse treatment market throughout the forecast period.
The rates of substance abuse have been steadily climbing in both developed and developing nations over the past decade. The World Drug Report 2022 revealed that around 275 million people worldwide used drugs at least once in 2021. The most commonly abused substances include opioids, cocaine, cannabis, amphetamines, and new psychoactive substances. This dramatic increase in substance abuse cases has led to a growing demand for effective treatment and rehabilitation services.
Leading pharmaceutical companies are investing heavily in research and development to create more potent and advanced therapeutic drugs for substance abuse treatment. In 2021, Indivior received FDA approval for Perseris, a long-acting injectable medication for treating schizophrenia in adults. The drug effectively reduces symptoms and lowers the risk of relapse due to substance abuse. Similarly, Teva launched a generic version of Suboxone film, a medication used for treating opioid dependence. The introduction of such groundbreaking drugs is expected to drive overall market growth in the years to come.
The global substance abuse treatment market is anticipated to experience a CAGR of 8.6% during the forecast period 2024-2031, driven by the increasing prevalence of drug abuse worldwide.
Market Segmentation
The market is segmented based on the following factors:
*
Type:
* Alcohol
* Opioids (e.g., heroin, prescription painkillers)
* Tobacco/nicotine
* Cocaine
* Marijuana
* Methamphetamines
* Other illicit drugs (Benzodiazepines, etc.)
*
Treatment Type:
* Opioid
* Methadone
* Buprenorphine
* Extended-release naltrexone
* Lofexidine
* Nicotine
* Nicotine replacement therapies (available as a patch, inhaler, or gum)
* Bupropion
* Varenicline
* Alcohol
* Naltrexone
* Disulfiram
* Acamprosate
* Tobacco
* Clonidine
* Nortriptyline
* Others (Topiramate, Modafinil, etc.)
*
Age Group:
* Adolescents
* Adults
* Geriatric
*
Treatment Setting:
* Outpatient Treatment
* Outpatient Clinics
* Private Practices
* Inpatient Treatment
* Rehabilitation Centers
* Hospitals
* Residential Treatment Facilities
* Detoxification Centers
*
Region:
* North America
* U.S.
* Canada
* Latin America
* Brazil
* Argentina
* Mexico
* Rest of Latin America
* Europe
* Germany
* U.K.
* Spain
* France
* Italy
* Russia
* Rest of Europe
* Asia Pacific
* China
* India
* Japan
* Australia
* South Korea
* ASEAN
* Rest of Asia Pacific
* Middle East
* GCC Countries
* Israel
* Rest of Middle East
* Africa
* South Africa
* North Africa
* Central Africa
Key Market Takeaways:
* The alcohol segment is expected to dominate the market based on type, reflecting its widespread harmful use.
* The opioid segment is anticipated to hold a significant share based on treatment type due to the escalating opioid addiction rates globally.
* The adolescent segment is projected to emerge as the largest segment based on age group, driven by rising drug experimentation at a young age.
* Outpatient treatment is anticipated to be the most preferred setting due to its convenience and lower costs.
* North America is projected to hold a dominant position in the market during the forecast period, attributed to high healthcare expenditure and the presence of key market players in the region.
Key Players
Major companies operating in the global substance abuse treatment market include:
* Indivior PLC
* Pfizer, Inc.
* Johnson & Johnson Inc.
* Alkermes
* Mallinckrodt Pharmaceuticals Inc.
* Teva Pharmaceutical Industries Ltd.
Recent Developments
*
January 2023:
Tempero Bio received approval from the U.S. FDA for its investigational new drug application for TMP-301, a lead candidate used to treat cocaine use disorder.*
May 2023:
Camurus announced that the U.S. Food and Drug Administration approved Brixadi extended-release injection for subcutaneous use, a weekly and monthly medication for treating moderate to severe opioid use disorder.The substance abuse treatment market is evolving rapidly, driven by the increasing prevalence of addiction and the development of innovative treatment options. This sector is expected to witness continued growth in the years to come, with digital therapeutics and new drug development playing key roles in shaping the future landscape of substance abuse treatment.
